Galapagos NV
Research Galapagos NV (GXE) on Bullrun: market cap EUR 1.62B, P/E 3.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGXE
- ExchangeF
- CountryBelgium
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 1.62B
- P/E3.3
- Financial periodFY2025
- RevenueEUR 1.11B
- Revenue growth303.5%
- Net incomeEUR 320.88M
- Free cash flow-EUR 271.16M
- Gross margin97.3%
Valuation Snapshot
latest market cap is EUR 1.62B; P/E is 3.3.
About Galapagos NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma;
Frequently asked questions
What is Galapagos NV's market cap?
Galapagos NV's market capitalization is EUR 1.62B.
What is Galapagos NV's P/E ratio?
Galapagos NV's price-to-earnings (P/E) ratio is 3.3.
What does Galapagos NV do?
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus;